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Background: Recent studies have demonstrated the influence of atherosclerotic risk
factors on the progression of aortic stenosis. We hypothesized that risk factors for
atherosclerosis might also be involved in the degeneration of pericardial heart valves
and might lead to reoperation as a result of structural valve failure, especially in
younger patients with high degeneration rates.
Methods: In 1984 and 1985, 161 patients (74% male; mean age, 54.4  1.0 years;
age range, 17-76 years; median age, 56.5 years) survived isolated aortic (n  137)
or combined aortic and mitral (n  25) valve replacement with a Hancock extra-
corporeal pericardial valve. Of these patients, 90 (56%) had reoperations as a result
of tissue failure of the aortic valve 5.6  0.25 years postoperatively.
Results: The patient group was split in half at the median age. In patients aged 57
years or younger, diabetes mellitus, female sex, cigarette smoking, and high cho-
lesterol and triglyceride levels were associated with accelerated valve failure. In a
multivariate model sex (female, P  .001), smoking (P  .001), diabetes mellitus
(P  .020), and cholesterol levels (P  .011) are risk factors for reoperation.
Patients without risk factors had reoperation after a mean of 9.25  0.88 years
compared with 4.05  0.43 years (P  .0002) in patients with 2 or 3 risk factors.
Conclusions: Risk factors of atherosclerosis might play a substantial role in the
degeneration of aortic bioprosthetic valves. Lowering of serum lipid levels, smoking
cessation, therapy for diabetes, and careful patient selection could be new strategies
to postpone degeneration. Younger patients could then possibly benefit from the
advantages of bioprostheses.
Degeneration of biologic heart valve prostheses is believed todepend on the mechanical properties of the valve and on immu-nologic and calcification processes. Degeneration of the nativevalve also involves mechanical stress and calcific and immuno-logic mechanisms. Recent studies demonstrated that risk factorsof atherosclerosis accelerate the progression of aortic stenosis.1
We hypothesized that these risk factors, including sex, cigarette smoking, diabetes
mellitus, and increased levels of cholesterol and triglycerides, might increase the
degeneration of biologic heart valves in patients after aortic valve replacement. The
hypothesis was tested by retrospectively investigating a group of patients who received
the Hancock pericardial valve in the mid-1980s at our institution. This patient group was
chosen because the valve had a high incidence of primary tissue failure with consecutive
reoperations, and lipid-lowering drugs were not in clinical use.
Methods
In 1984 and 1985, 161 patients (74% male; mean age, 54.4  11.0 years; age range, 17-76
years; median age, 56.5 years) survived isolated aortic (n  137) or combined aortic and
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mitral (n  25) valve replacement with a Hancock extracorpo-
real pericardial valve. Patients with significant concomitant
coronary artery disease were excluded from our study. Of these
161 patients, 90 (56%) had reoperations as a result of tissue
failure of the aortic valve 5.6  0.25 years postoperatively.
Because degeneration of biologic heart valves, the influence of
lipids on atherosclerosis, and lipid serum levels are known to be
age dependent,1,2 the patient group was split in half at the
median age. Preoperative patient characteristics of young (57
years) and elderly (57 years) patients are summarized in
Table 1. Patients were categorized as those with normal and
high cholesterol levels by using the commonly used cutoff point
at 240 mg/dL to analyze the influence of serum lipids on valve
failure. For triglyceride levels, the median value of 123 mg/dL
was used as the cutoff point.
Preoperative hypertension and renal failure are not presented
because preoperative hypertension obviously depends on aortic
valve disease, and renal failure was considered a contraindication.
Values are expressed as means and SEM. The Student t test was
used to compare absolute quantitative values. Reoperation, lon-
gevity of valves, and survival rates were calculated by using the
actuarial method and tested with the log-rank test. Every univariate
parameter reaching or approaching significance (P  .1) was then
tested in a Cox multivariate model.
Results
Reoperation as a Result of Tissue Failure
Data on reoperation as a result of tissue failure are shown in
Table 1 and Figure 1. In the entire patient population, none
of the investigated risk factors significantly influenced the
reoperation rate caused by tissue failure. Only smoking
tended to influence valve longevity negatively (P  .078).
Young patients (<57 years). In patients aged 57 years
or younger, diabetes mellitus, female sex, cigarette smok-
ing, and high cholesterol and triglyceride levels were asso-
ciated with accelerated valve failure. In a multivariate
model sex (female, P .001), smoking (P .001), diabetes
mellitus (P  .020), and high cholesterol levels (240
mg/dL, P  .011) are risk factors for reoperation. Patients
without risk factors had reoperation after a mean of 9.25 
0.88 years compared with 4.05  0.43 years (P  .0001) in
patients with 2 or 3 risk factors and 6.99  0.66 years in
patients 65 years or older (P  .124). In female patients
diabetes mellitus (18% vs 3%, P  .031) was more fre-
quent, and cholesterol (252 vs 220 mg/dL, P  .05) and
triglyceride levels (176 vs 137 mg/dL, P  .105) were
higher than in male patients.
TABLE 1. Preoperative patient characteristics
All
patients Young patients (<57 y) Elderly patients (>57 y)
P value n
Longevity of the valve, mean and
95% confidence interval (y)
P
value n
Longevity of the value, mean
and 95% confidence
interval (y)
P
value
Indication for AVR
AS .348 44 7.44 (5.96-8.91) .722 54 6.82 (5.33-8.32) .181
AR 42 7.45 (6.11-8.80) 21 8.24 (6.33-10.15)
Sex
Female .208 13 5.03 (3.93-6.13) .0047 36 7.46 (5.43-9.49) .923
Male 73 8.07 (6.89-9.26) 39 7.01 (5.81-8.20)
Cigarette smoking
Never .078 47 8.23 (6.85-9.61) .0119 49 7.5 (5.94-9.06) .707
History 26 6.34 (5.22-7.47) 17 6.35 (4.68-8.02)
Active 13 4.64 (3.98-5.31) 9 6.31 (4.31-8.48)
Diabetes mellitus
IDDM or NIDDM .574 4 3.95 (3.23-4.67) <.0001 10 6.71 (5.81-7.62) .264
No 82 7.65 (6.61-8.69) 65 7.08 (5.75-8.42)
Cholesterol [mg/dL]
240 mg/dL .601 54 8.42 (7.06-9.79) .0207 42 6.32 (5.36-7.28) .141
240 mg/dL 32 6.21 (4.30-8.12) 33 8.44 (6.39-10.49)
Triglyceride [mg/dL]
123 mg/dL .1384 43 8.66 (7.03-10.30) .0448 38 7.12 (5.85-8.39) .9243
123 mg/dL 43 6.29 (5.14-7.45) 37 7.59 (5.55-9.62)
Body mass index
25 kg/BSA2 .574 46 8.36 (6.77-9.95) .109 51 6.88 (5.29-8.48) .313
25 kg/BSA2 40 6.48 (5.44-7.52) 24 7.64 (5.96-9.32)
Parameters showing significant influence on valve longevity are printed in italics (P  .05) or bold (P  .01).
AVR, Aortic valve replacement; AS, aortic stenosis; AR, aortic regurgitation; BSA, body surface area; IDDM, insulin-dependent diabetes mellitus; NIDDM,
noninsulin-dependent diabetes mellitus.
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Elderly patients (>57 years). In elderly patients (57
years) valve longevity was not significantly influenced by
any of the investigated parameters.
Survival
None of the investigated risk factors had a significant effect
on survival after aortic valve replacement, and only smok-
ing tended to decrease life expectancy in younger patients
(P  .052).
Discussion
Despite the excellent hemodynamic properties of bioprosthe-
ses, aortic valve replacement with bioprostheses is generally
not advocated in patients younger than 65 years3 because
accelerated degeneration increases the risk of reoperation in
younger patients. In our study we demonstrate associations
between risk factors for atherosclerosis and degeneration of
aortic pericardial valves in younger but not in elderly patients,
suggesting additional mechanisms of degeneration in the
young age group.
Figure 1. Reoperation rate according to preoperative characteristics in younger patients (<57 years). Degenera-
tion of the Hancock pericardial aortic bioprosthesis leading to reoperation is substantially influenced by sex (a),
smoking habits (b), diabetes mellitus (c), cholesterol levels (d), and triglyceride levels (e). Indication for surgical
intervention had no effect on reoperation (f). OP, Operation; Chol, cholesterol; Trig, triglyceride; AR, aortic
regurgitation; AS, aortic stenosis.
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Premature failure of the second-generation Hancock ex-
tracorporeal pericardial valve was mainly caused by the
poorly designed stenting, leading to wear and tear of the
pericardial tissue. The valve was withdrawn from the mar-
ket because of the extraordinary high failure rate. In our
series 14 of the 90 exchanged aortic valves were investi-
gated by means of light and electron microscopy.4 Degen-
erated valves (13/14) had cusp tears originating at the bor-
der zones of the pericardium and the stent material. Valve
leaflets were thickened, and calcification was demonstrated
in the vast majority of valves (13/14). Electron microscopy
showed evidence of leukocyte infiltration of the collagen
matrix with phagocytosis and, as other features, lipid,
plasma protein, and calcium deposits. We hypothesized that
both factors, premature calcification and increased mechan-
ical stress, contributed to valve failure and that atheroscle-
rosis might be involved in the degeneration of aortic bio-
prostheses, as previously demonstrated for the native aortic
valve.1
Dyslipidemia indicated by high total cholesterol (240
mg/dL) levels was significantly associated with premature
valve degeneration; the effect of triglyceride levels was still
significant but minor. In elderly patients high cholesterol
and triglyceride levels had no effect on the reoperation rate.
However, the effect of total cholesterol as a risk factor
decreases in the elderly, and atherosclerosis is more closely
related to decreased levels of high-density lipoprotein cho-
lesterol.5 Unfortunately, data on cholesterol subfractions
were not available from our patients as a proof.
Interestingly, female sex is a risk factor for early degen-
eration of bioprostheses, which has been reported previous-
ly.2 With increasing age, the effect decreases, leading to the
hypothesis that sex hormones might be involved in degen-
erative processes. However, in our study female sex was
also associated with significantly higher preoperative levels
of cholesterol and triglycerides.
Although this study is of limited size and retrospective in
design, it is suggestive of the hypothesis that risk factors of
atherosclerosis play a substantial role in the degeneration of
aortic bioprosthetic valves. If this association is confirmed
in other bioprostheses (eg, porcine valves or third-genera-
tion pericardial valves), lowering of serum lipids, smoking
cessation, therapy for diabetes, and careful patient selection
could be strategies to postpone degeneration. Younger pa-
tients could then possibly benefit from the advantages of
bioprostheses.
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